New oral combo shows promise for rare blood cancer
NCT ID NCT02844309
First seen Feb 16, 2026 · Last updated May 16, 2026 · Updated 16 times
Summary
This study tested a three-drug oral regimen (thalidomide, cyclophosphamide, and dexamethasone) followed by maintenance therapy (thalidomide and prednisone) in 44 adults newly diagnosed with Waldenström macroglobulinemia, a rare blood cancer. The goal was to see how well the treatment controlled the disease. Participants had not received standard treatments like rituximab or bortezomib. The main measure was overall response rate, with progression-free survival also tracked.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for WALDENSTRÖM MACROGLOBULINEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Shuhua Yi
Tianjin, 300020, China
Conditions
Explore the condition pages connected to this study.